UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053886
Receipt number R000061511
Scientific Title In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye
Date of disclosure of the study information 2024/03/18
Last modified on 2024/03/18 14:07:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye

Acronym

In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye

Scientific Title

In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye

Scientific Title:Acronym

In vivo study of technical methods for reducing motion artifacts in dynamic MR imaging data of the human eye

Region

Japan


Condition

Condition

Healthy adult volunteer

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In an in vivo study of dynamic MR imaging of the human eye, we conduct data reanalysis focusing on both eye movement of the subjects and post-image processing to minimize ocular motion artifacts.

Basic objectives2

Others

Basic objectives -Others

In an in vivo study of dynamic MR imaging of the human eye, we conduct data reanalysis focusing on both eye movement of the subjects and post-image processing to minimize ocular motion artifacts.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of images before and after correction of eye movement using image processing, and evaluation of the validity of the numerical values obtained through correction analysis.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

40 years-old >

Gender

Male and Female

Key inclusion criteria

Healthy adults who have provided consent for secondary use were subjected to 1H-MR imaging as part of the clinical study 'Intraocular fluid dynamics measurement using O-17 stable isotope-labeled water in healthy adults' (jRCTs031210082) conducted from June 2021 to September 2021.

Key exclusion criteria

None

Target sample size

9


Research contact person

Name of lead principal investigator

1st name Takayuki
Middle name
Last name Obata

Organization

National Institutes for Quantum Science and Technology(QST)

Division name

Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan

TEL

043-206-3230

Email

obata.takayuki@qst.go.jp


Public contact

Name of contact person

1st name Takayuki
Middle name
Last name Obata

Organization

National Institutes for Quantum Science and Technology(QST)

Division name

Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science

Zip code

263-8555

Address

4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan

TEL

043-206-3230

Homepage URL


Email

obata.takayuki@qst.go.jp


Sponsor or person

Institute

National Institutes for Quantum Science and Technology(QST)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture Sports, Science and Technology

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Institutes for Quantum Science and Technology Certified Review Board

Address

4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan

Tel

043-206-4706

Email

helsinki@qst.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 03 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 02 Month 21 Day

Date of IRB

2024 Year 03 Month 12 Day

Anticipated trial start date

2024 Year 03 Month 18 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

observational study


Management information

Registered date

2024 Year 03 Month 18 Day

Last modified on

2024 Year 03 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061511


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name